CORV : Correvio Pharma Corp Stock Profile
Qayyum Rajan is a CFA Charterholder who has previously worked at CIBC, RBC Dominion Securities and Sentry Investments before creating his own fintech ventures.He has been a financial advisor, analyst and portfolio manager who is passionate about helping people reach their financial goals.Qayyum is the owner of Wealth Awesome where he writes financial content and creates tools for over 20,000 Canadian investors.
Expertises: finance, investment, stocks
Overview
Correvio Pharma Corp., a specialty pharmaceutical company, engages in developing therapeutics worldwide. Its products comprise Aggrastat (tirofiban hydrochloride), (an intravenous anti-platelet drug for patients with acute coronary syndrome; and Brinavess (vernakalant IV), a novel, atrial-preferential antiarrhythmic agent for the rapid conversion of recent onset atrial fibrillation to sinus rhythm. The company also offers Trevyent, a development stage drug/device combination product for pulmonary arterial hypertension; Xydalba, a treatment for acute bacterial skin and skin structure infections; and Zevtera/Mabelio, a cephalosporin antibiotic for intravenous administration with rapid bactericidal activity against a wide range of Gram-positive and Gram-negative bacteria. Correvio Pharma Corp. was incorporated in 2018 and is headquartered in Vancouver, Canada.
CORV.TO Stock Price and Key Stats
CORV Stock Key Stats
Exchange: TSX
Market Cap : $37.067MM
PE Ratio:
Price: (Updated: )
Correvio Pharma Corp (CORV) vs Competitors in Drug Manufacturers – Specialty & Generic
Lets see how CORV.TO stacks up against others in the Drug Manufacturers – Specialty & Generic asset management industry. We have identified its main peers as:Aleafia Health Inc, Aphria Inc, Acerus Pharmaceuticals Corporation, The Supreme Cannabis Company, Inc, Nuvo Pharmaceuticals Inc
.Drug Manufacturers – Specialty & Generic Industry Comparisons
Company | Market Cap ($MM) | P/E Ratio | EV/EBITDA | Dividend Yield |
---|---|---|---|---|
Aleafia Health Inc (ALEF) | $189.563 | N/A | 0.0 | 0.0% |
Aphria Inc (APHA) | $4,439.753 | N/A | 598.009 | 0.0% |
Acerus Pharmaceuticals Corporation (ASP) | $2.775 | N/A | -2.796 | 0.0% |
Correvio Pharma Corp (CORV) | $37.067 | N/A | 0.0 | 0.0% |
The Supreme Cannabis Company, Inc (FIRE) | $255.583 | N/A | 0.0 | 0.0% |
Comparisons within Drug Manufacturers – Specialty & Generic
- Correvio Pharma Corp (CORV) vs Aleafia Health Inc (ALEF)
- ALEF has higher EPS (-0.274 vs -0.879). ALEF has higher dividend yield (0.0% vs 0.0%). ALEF and CORV both have P/E’s under 0.
- Correvio Pharma Corp (CORV) vs Aphria Inc (APHA)
- APHA has higher EPS (0.116 vs -0.879). APHA has higher dividend yield (0.0% vs 0.0%). APHA and CORV both have P/E’s under 0.
- Correvio Pharma Corp (CORV) vs Acerus Pharmaceuticals Corporation (ASP)
- CORV has higher EPS (-0.879 vs -4.41). ASP has higher dividend yield (0.0% vs 0.0%). ASP and CORV both have P/E’s under 0.
- Correvio Pharma Corp (CORV) vs The Supreme Cannabis Company, Inc (FIRE)
- FIRE has higher EPS (-0.052 vs -0.879). FIRE has higher dividend yield (0.0% vs 0.0%). FIRE and CORV both have P/E’s under 0.
- Correvio Pharma Corp (CORV) vs Nuvo Pharmaceuticals Inc (NRI)
- NRI has higher EPS (0.024 vs -0.879). NRI has higher dividend yield (0.0% vs 0.0%). CORV has a P/E under 0, indicating NRI (P/E 2.6) is in a better position.
Our Recommendation: Hold
Features a lower EV/EBITDA ratio (0.00) than the industry average (2.71), indicating attractive valuation.
How to Buy CORV stock on the TSX
You can buy on pretty much any online brokerage in Canada, since it trades on the TSX.If you are looking for some easy options take a look at these two:Image | Product Title | Features | Price |
---|---|---|---|
Editor's Choice |
| Get $25 Signup Bonus | |
Reliable Pick |
| Get $50 Free Stock Trades |